Published in final edited form as:

J Am Chem Soc. 2011 September 28; 133(38): 14968–14971. doi:10.1021/ja207496p.

Direct Entry to Erythronolides via a Cyclic Bis[Allene]

Kai Liu^a, Hiyun Kim^a, Partha Ghosh^a, Novruz G. Akhmedov^b, and Lawrence J. Williams^{*,a}

^aDepartment of Chemistry, Rutgers, The State University of New Jersey, 610 Taylor Rd, Piscataway, NJ 08854

^bDepartment of Chemistry, West Virginia University, 406 Clark Hall, Prospect Street, Morgantown, WV 26506

Abstract

The complexity and low tractability of antibiotic macrolides pose serious challenges to addressing the problem of resistance through semi- or total synthesis. Here we describe a new strategy, the preparation of a complex, yet tractable, macrocycle, and the transformation of this macrocycle into a range of erythronolide congeners. These compounds represent valuable sectors of erythromycinoid structure space and constitute intermediates with the potential to gain further purchase in this space. The routes are short. The erythronolides were prepared in three or fewer steps from the macrocycle, which was prepared in a longest linear sequence of 11 steps.

Erythromycin is the archetypal macrolide and represents an important class of antibiotics.¹ Despite their structural complexity, erythromycin and its congeners have been used as front-line treatments for human infections, particularly of the respiratory tract. The erythromycin antibiotics are thought to exercise their protective properties primarily through blocking the elongation tunnel of domain V of the large ribosomal particle in bacteria.² Other functions include the selective uptake by macrophages, extracellular kinase activity, and perhaps anti-asthmatic function at low doses, among others.³ Many insights were derived from structural studies² and efforts to manipulate the polyketide synthase machinery.⁴ The largest contributions have come from the chemical synthesis of macrolides derived from erythromycin itself.⁵ The known structure/activity profile represents a herculean effort due to the intransigence of this natural product toward selective modification. Despite the considerable strides made in this area the erythromycin structure has not been evaluated fully, the typical modes of drug resistance continue to compromise effectiveness, and the central problem remains: limited access to erythromycinoid structure space severely retards the search for effective macrolide antibiotics.

Although unconventional for macrolides, we envisioned multiple targets as being derivable from a common, advanced macrocyclic intermediate (Figure 1, top). Previous syntheses of erythromycin aimed to demonstrate new methods or superior strategies to secure the natural product.⁶ Focused as they were on this single polyketide target, these routes are not necessarily relevant to the discovery of new antibiotic leads. Nevertheless, de novo synthesis represents a means by which to gain unrestricted access to erythromycinoid structure space. Only recently has total synthesis produced a new erythromycinoid antibiotic candidate, namely a desmethyl analog that is thought to have the potential to address resistance.⁷ The motif redundancy in erythromycin at C4-C6 and C10-C12 led us to consider allenic functionality in these regions (**IV**). The remaining C2-C3 and C8-C9 partners would

Corresponding Author: Lawrence J. Williams, lawjw@rci.rutgers.edu.

Supporting Information. Synthetic methods and detailed spectroscopic characterization data (HMBC, NOST, etc.). This material is available free of charge via the Internet at <http://pubs.acs.org>.

originate from opposite enantiomers of the same precursor. Thus an alkynol (**I**), an alkynal (**II**), and an aldehyde (**III**) would enable a convergent, recursive alkynylation sequence, coordinated allene installation, and then lactone formation. A model study suggested that a macrocycle with two allenyl groups positioned in this way would potentially undergo stereoselective and site selective modification.⁸

Our strategy was driven in part by the key features of the erythromycin structure/activity profile (bottom, Figure 1).⁵ In brief, prior studies suggest that: (a) portions of the glycans, especially the amino sugar, are critical and both the hydrophilic character of the β -face and the hydrophobic character of the α -face of the macrolide contribute to binding (center structure);⁵ⁱ (b) C9 amine or oxime functionality suppresses unwanted side effects (**V**);^{5c,f} (c) C9-C11 or C11-C12 heteroannulation can improve binding and appears to represent opportunities to overcome resistance (**VI**, **VII**);^{5b} (d) C6-C9 heterocyclization leads to interesting - albeit non-antibiotic - activity (**VIII**);^{5e} and (e) retention of the C6 and C12 heteroatom connectivity is desirable and ether formation at C6 may improve antibiotic activity and suppress other activity (**V**, **IX**).^{5g} C3 ketone derivatives^{5b} (**X**) and alterations to the hydrophobic face of the macrocycle (e.g. at C4, C8 and C10, **XI** and **XII**) may overcome resistance.^{2b,7} Hence, modification of the C3-C6 and C9-C12 regions offers opportunities to improve drug properties and avoid bacterial resistance.

Three components were prepared and joined to provide macrocycle **12** (Scheme 1). Addition of the enolate derived from oxazolidinone **1** to commercially available dimethoxy acetaldehyde afforded the expected aldol product as a single isomer (**2**, 90%).⁹ Subsequent benzyl ether formation ($\rightarrow$ **3**, 95%) and then hydride reduction provided the desired primary alcohol **4** (95%). A tosylate was derived from this alcohol and then without purification was subjected to lithium acetylide to give component **5** (82% over two steps). The antipode of **3** was exposed to mild acid and thereby furnished component **6** (95%, see inset). The alkynylide derived from **5** was combined with **6** in the presence of zinc bromide.¹⁰ The addition products spontaneously lactonized under the reaction conditions and the major product (**7**) was taken forward (64%, dr 8:1). Mild acid treatment of this acetal gave aldehyde **8** (90%). The alkynylide derived from component **9** was combined with **8** in the presence of chlorotriisopropoxytitanium,¹¹ and the major product (**10**) was taken forward (89%, dr 6:1). A single-flask procedure effected the conversion of the diyne to the corresponding bis[allene];¹² the crude material was then treated with mild acid to furnish **11** (88% over two steps). The seco acid smoothly lactonized and thus **12** was formed (64%).^{8,13}

Osmium tetroxide selectively converted the C4-C6 allenyl group of **12** into the hydroxyketone (**13**, 83% yield, Scheme 2). Reduction of the ketone cleanly gave **14** (68%).¹⁴ Triacetoxyborohydride¹⁵ reduction of the ketone gave the C5 epimer and sodium borohydride gave a 1:1 mixture of these products (data not shown). Silylation ($\rightarrow$ **15**, 83%) and then brief osmylation resulted in the formation of **16** (32%), a C9-C12 hydroxyenone. In contrast, osmylation of **13**, which contains a hydroxyl, produced bicycle **17** (50%). Similarly, double osmylation of **12** gave **17** directly (46%). Silylation of **17** gave **18** as a crystalline solid (78%, see Supporting Information for x-ray crystal structure).

Scheme 3 shows products derived from allene epoxidation.¹⁶ Exposure of **12** to DMDO in methanol smoothly delivered the C3-C6 alkoxyenone **19** (81%). Epoxidation with DMDO in chloroform¹⁷ followed by treatment with Lewis acid,¹² however, delivered the C3-C6 furanone **20**. Remarkably, lithium methylcyanocuprate promoted the formation of **20** in good yield (64%).^{8,17f}

Sequential allene osmylation and allene halohydratation¹⁸ is shown in Scheme 4. Following osmylation of **12**, the C4-C6 ketoalcohol **13** was transformed by NBS/water in MeCN into

the C11 bromo/C12 hydroxyl (**21**), which upon ketone reduction gave **22** (Scheme 4).¹⁴ Both of these reactions proceeded in excellent yield (>95%).

Allenes are central to this strategy. The coordinated synthesis of both allenes from **10** allowed the concurrent installation of the C12 and C6 methyl groups ($\rightarrow$ **11**, Scheme 1). However, the C6 allenyl group formed slowly in comparison to the C12 allenyl group, suggesting that the substituents need not be identical. The extended conformational constraints imposed by allenyl groups, relative to alkynyl and alkenyl functionality, and the presence of two such groups in seco acid **11** probably facilitate the macrocyclization.^{6j} The four sites of unsaturation housed within **12** were transformed with apparently complete selectivity (Schemes 2–4). The observed order of reactivity is C5–C6, C4–C5, C11–C12, and then C10–C11. The C5–C6 π -bond was expected to be most reactive due to high substitution and since the reactivity of the C11–C12 π -bond is attenuated by the C13 ester. After oxygen delivery to C5–C6, via epoxidation or osmylation, the C4–C5 π -bond is the most highly reactive nucleophilic site of unsaturation remaining.⁸ The allenyl groups also provide a topological bias. In all of the allene reactions shown the products were isolated as single isomers. The outcomes reflect the cooperative effects of intrinsic allene stereoselectivity, macrocyclic stereocontrol,¹⁹ and, for the intramolecular transformations, proximity of the reacting partners. Although late-stage modification of isolated π -bonds is a known strategy in terpene syntheses,²⁰ it is rare in macrolide synthesis,^{6g} and the use of cyclic bis[allenes] in synthesis is rarer still.²¹

Allene oxidation methods are underutilized. For example, a disproportionately small number of allene osmylation²² reports appear in the literature relative to alkene osmylation.²³ Although allene osmylation is not well studied, it is clear that the osmium adducts formed and hydrolyzed (e.g. **23** $\rightarrow$ **13**, **24** $\rightarrow$ **25**, Scheme 5). Unlike simple alkene-derived osmate esters, these intermediates are also enolates.²⁴ β -Elimination and subsequent intramolecular conjugate addition is reasonable. Interestingly, the C3 benzyloxy group is retained whereas the C9 group is lost. These phenomena are most likely traceable to the stereoelectronics of the osmate ester intermediates.²⁵

We suggest that formation of **19** and **20** is closely related and involves allene oxide opening (**26** $\rightarrow$ **27**), or spirodiepoxide opening (**29** $\rightarrow$ **30**), and capture of the C-3 benzyloxy group (Scheme 6). The transfer of benzyloxy from C3 to C6 may well be promoted by 3,4-elimination in the case of **19**. The analogous spirodiepoxide pathway is interrupted and the benzyl group is lost under conditions that lead to **20**. Interestingly, the configuration at C6 in **19** is opposite that of **20**. This may reflect the comparatively high stability of oxyallyl zwitterion **27**, which could explain benzyloxy capture with overall retention of configuration at C6. In the case of **29**, the comparatively low stability of a cation derived from the spirodiepoxide combined with the proximity of the C3 OBn to C6 could lead to **30** directly with inversion at C6. This mechanistic framework is also consistent with the reaction conditions used for these transformations. We favor this rationale, but further studies are needed to evaluate these hypotheses.

The face selectivity of the allene halohydrate differs from the allene oxidation reactions. Nevertheless, the *Z*-bromo/ β -C12 hydroxyl of **22** was expected. Whereas oxidation occurs from the most accessible face of the reacting allenyl double bond, bromination occurs from the less accessible face and water adds to the more accessible face (mechanism not shown). These reactions have not been studied in complex allenes; however, this sort of selectivity is well known for acyclic systems.¹⁸

This strategy focuses on substances that can be called upon to react along differing pathways.²⁶ The longest linear sequence to **12** is 11 steps and compounds **13–22** were

prepared from this intermediate in 3 or fewer steps; this compares well to previous work in the area.^{6,7} Compound **12** is a processable intermediate that integrates the routes to targets that occupy underexplored erythromycinoid structure space, including valuable desmethyl, cyclic, and other functionalized variants. Taken together, the convergent assembly of **5**, **6**, and **9**, the conversion of **10** to **11**, and the reactions summarized in Schemes 2–4 suggest a realistic route by which to effect extensive and expeditious changes to the macrolide scaffold represented by erythromycin.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This paper is dedicated to Professor Samuel J. Danishefsky on the occasion of his 75th birthday. Financial support from the NIH (GM078145) is gratefully acknowledged.

References

1. a) Lonks JR, Goldmann DA. Clin Infect Dis. 2005; 40:1657. [PubMed: 15889365] b) Omura, S. Macrolide Antibiotics: Chemistry, Biology, and Practice. 2. Elsevier Science; San Diego: 2002. c) Wu Y, Su W. Curr Med Chem. 2001; 8:1727. [PubMed: 11562291] d) Zhanel GG, Dueck M, Hoban DJ, Vercaigne LM, Embil JM, Gin AS, Karlowsky JA. Drugs. 2001; 61:443. [PubMed: 11324679] e) Wu Y. Curr Pharm Des. 2000; 6:181. [PubMed: 10637376]
2. a) Bulkley D, Innis CA, Blaha G, Steitz TA. Proc Natl Acad Sci USA. 2010; 107:17158. [PubMed: 20876130] b) Dunkle JA, Xiong L, Mankin AS, Cate JHD. Proc Natl Acad Sci USA. 2010; 107:17152. [PubMed: 20876128] c) Tu D, Blaha G, Moore PB, Steitz TA. Cell. 2005; 121:257. [PubMed: 15851032] d) Schlunzen F, Zarivach R, Harms J, Bashan A, Tocilj A, Albrecht R, Yonath A, Franceschi F. Nature. 2001; 413:814. [PubMed: 11677599] e) Nissen P, Hansen J, Ban N, Moore PB, Steitz TA. Science. 2000; 289:920. [PubMed: 10937990] f) Yonath A, Leonard K, Wittmann H. Science. 1987; 236:813. [PubMed: 3576200]
3. Shinkai M, Henke MO, Rubin BK. Pharmacol & Therapeut. 2008; 117:393.
4. a) Khosla C, Tang Y, Chen AY, Schnarr NA, Cane DE. Annu Rev Biochem. 2007; 76:195. [PubMed: 17328673] b) Katz L. Chem Rev. 1997; 97:2557. [PubMed: 11851471] c) Khosla C. Chem Rev. 1997; 97:2577. [PubMed: 11851472] d) Hutchinson CR, Fujii I. Annu Rev Microbiol. 1995; 49:201. [PubMed: 8561459]
5. a) Lewis CA, Miller SJ. Angew Chem, Intl Ed. 2006; 45:5616. b) Agouridas C, Denis A, Auger J, Benedetti Y, Bonnefoy A, Bretin F, Chantot F, Dussarat A, Fromentin C, D'Ambrières SG, Lachaud S, Laurin P, Martret OL, Loyau V, Tessot N. J Med Chem. 1998; 41:4080. [PubMed: 9767644] c) Gasc JC, d'Ambrières SG, Lutz A, Chantot JF. J Antibiot. 1991; 44:313. [PubMed: 1827435] d) Retsema JA, Girard AE, Schekly W, Manousos M, Anderson MR, Bright GM, Borovoy RJ, Brennan LA, Mason R. Antimicrob Agents Chemother. 1987; 31:1939. [PubMed: 2449865] e) Omura S, Tsuzuki K, Sunazuka T, Marui S, Toyoda H, Inatomi N, Itoh Z. J Med Chem. 1987; 30:1941. [PubMed: 3669001] f) Chantot JF, Bryskier A, Gasc JC. J Antibiot. 1986; 39:660. [PubMed: 3733515] g) Morimoto S, Takahashi Y, Watanabe Y, Omura S. J Antibiot. 1984; 37:187. [PubMed: 6706855] h) Allen N. Antimicrob Agents Chemother. 1977; 11:669. [PubMed: 856018] i) Mao JC-H, Putterman M. J Mol Biol. 1969; 44:347. [PubMed: 5406454]
6. a) Muri D, Carreira EM. J Org Chem. 2009; 74:8695. [PubMed: 19839571] b) Muri D, Lohse-Fraefel N, Carreira EM. Angew Chem, Intl Ed. 2005; 44:4036. c) Peng Z, Woerpel KA. J Am Chem Soc. 2003; 125:6018. [PubMed: 12785807] d) Toshima K, Nozaki Y, Mukaiyama S, Tamai T, Nakata M, Tatsuta K, Kinoshita M. J Am Chem Soc. 1995; 117:3717. e) Stuermer R, Ritter K, Hoffmann RW. Angew Chem, Intl Ed. 1993; 32:105. f) Tone H, Nishi T, Oikawa Y, Hikota M, Yonemitsu O. Chem Pharm Bull. 1989; 37:1167. g) Paterson I, Rawson DJ. Tetrahedron Lett. 1989; 30:7463. h) Stork G, Rychnovsky SD. J Am Chem Soc. 1987; 109:1565. i) Woodward RB, et al. J Am Chem Soc. 1981; 103:3210. j) Woodward RB, et al. J Am Chem Soc. 1981; 103:3213. k)

- Woodward RB, et al. *J Am Chem Soc.* 1981; 103:3215. Degradation: D) LeMahieu RA, Carson M, Kierstead RW, Fern LM, Grunberg E. *J Med Chem.* 1974; 17:953. [PubMed: 4213128]
7. Velvadapu V, Paul T, Wagh B, Klepacki D, Guvench O, MacKerell A, Andrade RB. *ACS Med Chem Lett.* 2011; 2:68. [PubMed: 21643527] See also: Gerber-Lemaire S, Ainge SW, Glanzmann C, Vogel P. *Helv Chem Acta.* 1998; 81:1439.
8. Ghosh P, Zhang Y, Emge TJ, Williams LJ. *Org Lett.* 2009; 11:4402. [PubMed: 19725523]
9. Evans DA, Bartroli J, Shih TL. *J Am Chem Soc.* 1981; 103:2127.
10. Mead KT. *Tetrahedron Lett.* 1987; 28:1019.
11. Shimizu M, Kawamoto M, Niwa Y. *Chem Commun.* 1999:1151.
12. Sharma R, Manpadi M, Zhang Y, Kim H, Akhmedov NG, Williams LJ. *Org Lett.* 2011; 13:3352. [PubMed: 21648404]
13. Inanaga J, Hirata K, Saeki H, Katsuki T, Yamaguchi M. *Bull Chem Soc Jpn.* 1979; 52:1989.
14. C.f. ref. 6g for a closely related substrate and transformation.
15. Evans DA, Chapman KT, Carreira EM. *J Am Chem Soc.* 1988; 110:3560.
16. a) Kim H, Williams LJ. *Curr Opin Drug Discovery Dev.* 2008; 11:870. b) Horvath, A.; Backvall, J. *Modern Allene Chemistry.* Krause, N.; Hashmi, ASK., editors. Vol. 2. Wiley-VCH Verlag; Weinheim: 2004. p. 973-994. c) Rameshkumar C, Xiong H, Tracey MR, Berry CR, Yao LJ, Hsung RP. *J Org Chem.* 2002; 67:1339. [PubMed: 11846684] d) Crandall JK, Batal DJ, Lin F, Reix T, Nadol GS, Ng RA. *Tetrahedron.* 1992; 48:1427.
17. a) Joyasawal S, Lotesta SD, Akhmedov NG, Williams LJ. *Org Lett.* 2010; 12:988. [PubMed: 20121257] b) Ghosh P, Cusick JR, Inghrim J, Williams LJ. *Org Lett.* 2009; 11:4672. [PubMed: 19810767] c) Zhang Y, Cusick JR, Ghosh P, Shangguan N, Katukojvala S, Inghrim J, Emge TJ, Williams LJ. *J Org Chem.* 2009; 74:7707. [PubMed: 19761213] d) Wang Z, Shangguan N, Cusick JR, Williams LJ. *Synlett.* 2008:213. e) Lotesta SD, Kiren S, Sauers RR, Williams LJ. *Angew Chem, Intl Ed.* 2007; 46:7108. f) Ghosh P, Lotesta SD, Williams LJ. *J Am Chem Soc.* 2007; 129:2438. [PubMed: 17288427] g) Lotesta SD, Hou Y, Williams LJ. *Org Lett.* 2007; 9:869. [PubMed: 17286409] h) Katukojvala S, Barlett KN, Lotesta SD, Williams LJ. *J Am Chem Soc.* 2004; 126:15348. [PubMed: 15563139]
18. a) Ma, S. *Modern Allene Chemistry.* Krause, N.; Hashmi, ASK., editors. Vol. 2. Wiley-VCH Verlag; Weinheim: 2004. p. 595. b) Waters WL, Linn WS, Caserio MC. *J Am Chem Soc.* 1968; 90:6741.
19. Still WC, Galynker I. *Tetrahedron.* 1981; 37:3981.
20. Cakmak M, Mayer P, Trauner D. *Nat chem.* 2011; 3:543. [PubMed: 21697875]
21. For early studies on related cyclic allenes, see: Nicolaou KC, Garratt PJ, Sondheimer F. *J Am Chem Soc.* 1973; 95:4582.
22. a) Fleming SA, Liu R, Redd JT. *Tetrahedron Lett.* 2005; 46:8095. b) Fleming SA, Carroll SM, Hirschi J, Liu R, Pace JL, Redd JT. *Tetrahedron Lett.* 2004; 45:3341. c) Mereyala HB, Gurrula SR, Mohan SK. *Tetrahedron.* 1999; 55:11331. d) Manabe S. *Chem Commun.* 1997; 8:737. e) David K, Ariento C, Greiner A, Gore J, Cazes B. *Tetrahedron Lett.* 1996; 37:3335. f) Wolff S, Agosta WC. *Can J Chem.* 1984; 62:2429. g) Biollaz M, Haefliger W, Velarde E, Crabbe P, Fried JH. *J Chem Soc Chem Commun.* 1971; 21:1322.
23. Kolb HC, VanNieuwenhze MS, Sharpless KB. *Chem Rev.* 1994; 94:2483.
24. Azam KA, Deeming AJ. *J Chem Soc Dalton.* 1981; 1:91.
25. The scope of allene osmylation, and conformational, computational, and additional synthetic details will be disclosed separately.
26. a) Drahl MA, Akhmedov NG, Williams LJ. *Tetrahedron Lett.* 2011; 52:325. b) Xu D, Drahl MA, Williams LJ. *Beilstein J Org Chem.* 2011; 7:937. [PubMed: 21804888] C.f.: c) Jones SB, Simmons B, Mastracchio A, MacMillan DWC. *Nature.* 2011; 475:183. [PubMed: 21753848] d) Wilson RM, Danishefsky SJ. *Angew Chem, Intl Ed.* 2010; 49:6032. e) Burns NZ, Baran PS, Hoffmann RW. *Angew Chem, Intl Ed.* 2009; 48:2854. f) Schreiber SL. *Nature.* 2009; 457:153. [PubMed: 19129834] g) Hendrickson JB. *J Am Chem Soc.* 1971; 93:6847.

Figure 1.
Recursive assembly of a macrocyclic bis[allene] (top) and functional macrolide motifs (bottom).

Scheme 1. Synthesis of 12^a

^aConditions: (a) *n*-Bu₂BOTf, NEt₃, DCM, -78 °C, then (MeO)₂CHCHO, warm to 0 °C, 90%; (b) BnBr, Ag₂O, DCM, rt, 95%; (c) LiBH₄, Et₂O, 0 °C, 95%; (d) DABCO, TsCl, DCM, 0 °C; (e) lithium acetylide ethylenediamine complex, DMSO, 15 °C, 82% (2 steps); (f) HOAc, H₂O, CF₃CO₂H, rt, 95%; (g) *n*-BuLi, ZnBr₂, Et₂O, -78 °C to 0 °C then 6, 64%, dr = 8:1; (h) HOAc, H₂O, CF₃CO₂H, rt, 90%; (i) 9, MeLi, Ti(O*i*Pr)₃Cl, THF, -78 °C, then 8, -78 °C to -40 °C, 89%, dr = 6:1; (j) MsCl, NEt₃, Et₂O, rt, cool to -20 °C, MeCuCNLi, -20 °C to rt; (k) HOAc, H₂O, CF₃CO₂H, rt, 88% (2 steps); (l) 2,4,6-trichlorobenzoylchloride, NEt₃, DMAP, tol, rt, 80 °C, 64%.

Scheme 2. Erythronolides via osmylation^a

^aConditions: (a) OsO₄, *t*-BuOH, H₂O, rt, 83%; (b) Zn(BH₄)₂, Et₂O, 0 °C, 68%; (c) TESOTf, 2,6-lut, DCM, rt, 83%; (d) OsO₄, *t*-BuOH, H₂O, rt, 32%; (e) OsO₄, *t*-BuOH, H₂O, rt, 50%; (f) OsO₄, *t*-BuOH, H₂O, rt, 46%; (g) TE-SOTf, 2,6-lut, DCM, rt, 78%.

Scheme 3. Erythronolides via epoxidation^a

^aConditions: (a) DMDO, CH₃OH, -50 °C to -15 °C, 81%; (b) DMDO, CHCl₃, -40 °C to -15 °C, then MeCuCNLi, 2-methyl-THF, -15 °C, 64%.

Scheme 4. Erythronolides via combined methods^a

^aConditions: (a) NBS/H₂O, MeCN, rt, 99%; (b) Zn(BH₄)₂, Et₂O, 0 °C, 98%.

Scheme 5.
Mechanistic rationale for Osmylation of 12.

Scheme 6.
Mechanistic rationale for epoxidation of 12.